[A26-33] Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Addendum to Project A25-147
Last updated 07.05.2026
Project no.:
A26-33
Commission:
Commission awarded on 24.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Treatment of symptomatic, inoperable plexiform neurofibromas in adult patients with neurofibromatosis type 1
After addendum now: hint of a minor added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A26-33
| Project no. | Title | Status |
|---|---|---|
| A25-147 | Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07-05-2026 A G-BA decision was published.
G-BA documents on this decision